8-K: Atara Biotherapeutics Reports Q1 2024 Financials and Pipeline Progress, BLA Submission for Tab-cel on Track

Atara Biotherapeutics announced its first quarter 2024 financial results and provided updates on its clinical programs, including the planned submission of a Biologics License Application (BLA) for tab-cel in Q2 2024.

Summary

• Atara Biotherapeutics reported a net loss of $31.8 million, or $0.23 per share, for the first quarter of 2024, compared to a net loss of $74.8 million, or $0.72 per share, for the same period in 2023.
• The company's total revenue for Q1 2024 was $27.4 million, a significant increase from $1.2 million in Q1 2023, primarily due to revenue from the expanded partnership with Pierre Fabre.
• Research and development expenses decreased to $45.5 million in Q1 2024 from $62.2 million in Q1 2023.
• Atara's cash, cash equivalents, and short-term investments totaled $46.2 million as of March 31, 2024, with accounts receivable of $35.8 million, bringing the total to $82.1 million.
• The company expects its cash runway to extend into 2027, supported by anticipated milestone payments and operational efficiencies.
• Atara plans to submit a BLA for tab-cel in Q2 2024 and expects to initiate a Phase 1 study of ATA3219 in lupus nephritis in Q4 2024.
• Initial clinical data for ATA3219 in non-Hodgkin's lymphoma is expected in Q4 2024, and initial data for lupus nephritis is expected in the first half of 2025.
• The company anticipates a 35% decrease in full-year 2024 operating expenses compared to 2023.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook with improved financials, progress in clinical programs, and a strong cash runway. However, the company is still operating at a loss and faces risks associated with clinical development and regulatory approvals.

Positives

• The company's revenue increased significantly year-over-year due to the Pierre Fabre partnership.
• Net losses have decreased substantially compared to the same period last year.
• The BLA submission for tab-cel is on track for Q2 2024.
• The company has a strong cash position and runway into 2027.
• Operating expenses are expected to decrease significantly in 2024.
• Multiple clinical milestones are expected in the near term for ATA3219.
• The company received a $20 million milestone payment from Pierre Fabre in April 2024.

Negatives

• The company still reported a net loss of $31.8 million for the quarter.
• Research and development expenses remain high at $45.5 million for the quarter.
• The company has a history of losses and is reliant on milestone payments and partnerships for funding.

Risks

• The company's financial performance is dependent on the success of its clinical programs and partnerships.
• There are risks associated with the regulatory approval process for tab-cel.
• Clinical trials for ATA3219 may not yield positive results.
• The company's cash runway is dependent on receiving milestone payments and achieving operational efficiencies.
• The company is subject to risks associated with the pharmaceutical product development process, including clinical trial success and regulatory approvals.
• The COVID-19 pandemic and geopolitical events could impact the company's operations and financial condition.

Future Outlook

Atara expects its cash runway to extend into 2027, supported by anticipated milestone payments, operational efficiencies, and the planned transition of tab-cel activities to Pierre Fabre. The company anticipates a 35% decrease in full-year 2024 operating expenses compared to 2023.

Management Comments

• Pascal Touchon, President and Chief Executive Officer of Atara, stated that ATA3219 is advancing as a promising new therapeutic option for oncology and autoimmune diseases.
• He also noted that the partnership with Pierre Fabre continues to generate value, with the first milestone payment received in April.

Industry Context

This announcement is relevant to the broader cell therapy industry, particularly in the areas of allogeneic T-cell therapies and CAR T-cell development. Atara's focus on EBV T-cell biology and its potential to address limitations of autologous and allogeneic CAR therapies positions it as a key player in the field.

Comparison to Industry Standards

• Atara's 48.8% Objective Response Rate (ORR) for tab-cel in the ALLELE study is a positive result compared to other treatments for post-transplant lymphoproliferative disease (PTLD).
• The company's approach to allogeneic CAR T-cell therapy, which maintains the native EBV TCR, is a differentiated approach compared to gene-edited approaches used by companies like CRISPR Therapeutics and Allogene Therapeutics.
• The planned expansion of ATA3219 into multiple autoimmune indications is similar to strategies employed by companies like Kyverna Therapeutics, which is also exploring CAR T-cell therapy for autoimmune diseases.
• The partnership with Pierre Fabre is a significant deal, comparable to other large pharmaceutical collaborations in the cell therapy space, such as the collaboration between Gilead and Kite Pharma.

Related Party Transactions

• The document details the expanded global partnership with Pierre Fabre Laboratories, including upfront payments, potential milestone payments, and royalties on net sales.

Stakeholder Impact

• Shareholders will be impacted by the improved financial results and progress in clinical programs.
• Employees may be impacted by the ongoing restructuring and workforce reductions.
• Patients with cancer and autoimmune diseases may benefit from the development of new therapies.
• The partnership with Pierre Fabre will impact the company's financial stability and future growth.

Next Steps

• Submit a Biologics License Application (BLA) for tab-cel in Q2 2024.
• Initiate a Phase 1 study of ATA3219 in lupus nephritis in Q4 2024.
• Expand the Phase 1 study of ATA3219 into a new cohort in severe SLE without lymphodepletion in Q4 2024.
• Continue enrollment in the Phase 1 study of ATA3219 in non-Hodgkin's lymphoma.
• Progress towards an IND submission for ATA3431 in H2 2025.
• Transition substantially all activities relating to tab-cel to Pierre Fabre potentially as early as Q1 2025.

Key Dates

Keywords

Atara Biotherapeutics, Tab-cel, ATA3219, AlloCAR-T, Epstein-Barr virus, BLA, Lupus Nephritis, Non-Hodgkins Lymphoma, T-cell immunotherapy, Pierre Fabre, Financial Results, Clinical Trials